Key facts
- It has raised $2.0M across 2 recorded rounds; the latest was Seed Round ($1.4M) in May 2025.
- Notable investors include US National Science Foundation, United States Department of War, Evolution VC Partners.
- Infusense has filed 2 Form Ds with the SEC since 2015, most recently Jun 2025 ($1.4M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Infusense
Funding rounds
2 roundsAbout Infusense
Developer of a biosensor platform designed for precise drug quantification. The company's platform leverages electrochemical technology to provide rapid, sensitive sample analysis, enabling healthcare providers and researchers to perform drug detection and analysis with laboratory-grade accuracy in a portable format.
- Sector
- Healthcare
- HQ
- Nashville, TN, United States
- Founded
- 2009
- Employees
- 8
- Website
- infusense.com/
- Ownership
- Privately Held (backing)
Infusense doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Infusense shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Infusense in its N-PORT filings yet. We sweep new filings monthly.